HEBERPROT-P
HEBERPROT-P contains human epidermal growth factor which is produced by recombinant DNA technology. When directly injected into the wound, this growth factor ensures healing of deep and serious diabetic foot ulcers that are induced by diabetes and may usually lead to amputation of the foot. It has gained an important place among the treatments of diabetic foot ulcers and those addressing the prevention of diabetes-induced foot amputation (removal). When applied to diabetic foot ulcers associated with impaired blood flow into the tissue or nerve damage, HEBERPROT-P provides a fast, safe and effective wound healing process. In addition, HEBERPROT-P has significantly reduced the rates of foot amputation caused by diabetes-induced foot ulcers in 26 countries where it is already registered.
This product contain 19 published clinical trials.
| Authors | Article | Journal | |
|---|---|---|---|
| Meltem IŞIKGÖZ TAŞBAKAN1, Ilgın YILDIRIM ŞİMŞİR2,*, Sinan MERMER1, Serhat UYSAL3, Murat ÖZTÜRK4, Şevki ÇETİNKALP2 | Intralesional epidermal growth factor therapy for diabetic foot ulcers: an evaluation of 15 cases | Turk J Med Sci (2017) 47: 1500-1504 © TÜBİTAK doi:10.3906/sag-1703-153 | |
| Bulent M. Ertugrul, MD, Benjamin A. Lipsky, MD , Ulas Guvenc, MD and the Turkish Intralesional Epidermal Growth Factor Study Group for Diabetic Foot Wounds | An Assessment of Intralesional Epidermal Growth Factor for Treating Diabetic Foot Wounds | The First Experiences in Turkey Journal of the American Podiatric Medical Association _ Vol 107 _ No 1 _ Month/Month 2017 | |
| Herrera AIG, Sanabria RDJF, Cartaya MM (2017) | The Effectiveness of Achilles Lengthening Plus Intralesional Human Recombinant Epidermal Growth Factor to Prevent Recidivism of Neuropathic Diabetic Forefoot Ulceration. | Clin Res Foot Ankle 5: 248. doi: 10.4172/2329-910X.1000248 | |
| Aristides L. Garcia Herrera, | Intralesional administration of human recombinant epidermal growth factor improves healing and reduces amputations in patients with severe diabetic foot ulcers | Current Therapeutic Research, http://dx.doi.org/10.1016/j.curtheres.2017.03.004 | |
| Şamil AKTAŞ, Selçuk BAKTIROĞLU, Levent DEMİR , Önder KILIÇOĞLU , Murat TOPALAN ,Erdem GÜVEN , Bengüsu MİRASOĞLU , Fatih YANAR | Intralesional application of epidermal growth factor in limb-threatening ischemic diabetic foot ulcers | Acta Orthop Traumatol Turc 2016;50(3):277–283 doi: 10.3944/AOTT.2015.14.0434 | |
| Ojalvo AG, Acosta JB, Marí YM, Mayola MF, Pérez CV, Gutiérrez WS, Marichal II, Seijas EÁ, Kautzman AM, Pacheco AE, Armstrong DG. | Healing enhancement of diabetic wounds by locally infiltrated epidermal growth factor is associated with systemic oxidative stress reduction. | Int Wound J 2016; doi: 10.1111/iwj.12592 | |
| Mert Dumantepe, Osman Fazliogullari, Mustafa Seren , Ibrahim Uyar , and Fahrettin Basar | Efficacy of intralesional recombinant human epidermal growth factor in chronic diabetic foot ulcers Growth Factors, | Early Online: 1–5 2015 Informa UK Ltd. DOI: 10.3109/08977194.2015.1031898 | |
| Ramiro Gomez-Villa, MD1; Francisco Aguilar-Rebolledo, MD, PhD2; Adriana Lozano Platon off, MD1; Juan Miguel Teran-Soto, MD2; Maria Rosy Fabian-Victoriano, ETN1; Nicole Stephanie Kresch-Tronik, MD1; Ximena Garrido-Espíndola, ETN1; Adriana Garcia-Solis, MD | Efficacy of intralesional recombinant human epidermal growth factor in diabetic foot ulcers in Mexican patients: A randomized double-blinded controlled trial Wound Rep Reg | (2014) 22 497–503 © 2014 by the Wound Healing Society DOI:10.1111/wrr.12187 | |
| López-Saura PA, Yera-Alos IB, Valenzuela-Silva C, González-Díaz O, Río-Martín Ad, et al. (2013) | Medical Practice Confirms Clinical Trial Results of the Use of Intralesional Human Recombinant Epidermal Growth Factor in Advanced Diabetic Foot Ulcers. | Adv Pharmacoepidem Drug Safety 2: 128. doi:10.4172/2167-1052.1000128 | |
| Isis B Yera-Alos 1, Liuba Alonso-Carbonell1, Carmen M Valenzuela-Silva 2, Angela D Tuero-Iglesias 2, Martha Moreira-Martínez 3, Ivonne Marrero-Rodríguez 4, Ernesto López-Mola 2 and Pedro A López-Saura 2 | Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers | Yera-Alos et al. BMC Pharmacology and Toxicology 2013, 14:44 http://www.biomedcentral.com/2050-6511/14/44 | |
| Berlanga-Acosta J. | Diabetic lower extremity wounds: the rationale for growth factors-based infiltration treatment. | Int Wound J 2011; doi: 10.1111/j.1742-481X.2011.00840.x | |
| José Fernández Montequin, Gabriela Mena , Llipsy Santiesteban | Treatment and recovery of Wagner 5 diabetic foot with Heberprot-P. | Biotecnología Aplicada 2010;27:113-115 | |
| Wilver Velázquez1, Alfredo Valles2, Walfrido Curbelo3 | Impact of epidermal growth factor on the treatment of diabetic foot ulcers. | Biotecnología Aplicada 2010;27:136-141 | |
| Miriela R Gil1, Ernesto López-Mola1, Héctor Álvarez2, Ariadna Hernández1, Caridad Pérez3, Isis Yera4, Leoncio Padrón5, José A Llanes2, Ricardo Silva1, María del Carmen Abrahantes1, Julio Baldomero1, Amaurys del Río1, Rafael Ibargollín 6, Luis He | Experiences in the nationwide program for the integral care of the patient with diabetic foot ulcer using Heberprot-P | Biotecnología Aplicada 2010;27:147-150 | |
| Fern ´ andez-Montequ´ın JI, Valenzuela-Silva CM, Gonza´ lez Dı´az O, Savigne W, Sancho-Soutelo N, Rivero-Ferna´ ndez F, S ´ anchez-Penton P, Morej ´ on-Vega L, Artaza-Sanz H, Garc´ıa-Herrera A, Gonza´ lez-Benavides C, Herna´ ndez- Can˜ ete C | Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study. | Int Wound J 2009; 6:432–443 | |
| Ferna´ ndez-Montequı´n JI, Betancourt BY, Leyva-Gonzalez G, Mola EL, Gala´ n-Naranjo K, Ramı´rez-Navas M, Bermu´ dez-Rojas S, Rosales F, Garcı´a-Iglesias E, Berlanga-Acosta J, Silva-Rodriguez R, Garcia-Siverio M, Martinez LH. | Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure. | Int Wound J 2009;6:67–72. | |
| Berlanga-Acosta J, Gavilondo-Cowley J, Lo´ pez-Saura P, Gonza´ lez-Lo´ pez T, Castro-Santana MD, Lo´ pez-Mola E, Guille´ n-Nieto G, Herrera-Martinez L. | Epidermal growth factor in clinical practice–a review of its biological actions, clinical indications and safety implications. | Int Wound J 2009; 6:331–346 | |
| Ferna´ ndez-Montequı´n JI, Infante-Cristia´ E, Valenzuela-Silva C, Franco-Pe´ rez N, Savigne-Gutierrez W, Artaza-Sanz H, Morejo´ n-Vega L, Gonza´ lez-Benavides C, Eliseo-Musenden O, Garcı´a-Iglesias E, Berlanga-Acosta J, Silva- Rodrı´guez R, Be | Intralesional injections of Citoprot-P_ (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. | Int Wound J 2007;4:333–343. | |
| Acosta JB, Savigne W, Valdez C, Franco N, Alba JS, del Rio A, Lo´ pez-Saura P, Guille´ n G, Lopez E, Herrera L, Fe´ rnandez-Montequı´n J. | I. Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds. | Int Wound J 2006;3:232–239. |
Information on our site, physician or pharmacist can not replace the information received in consultation. Hasbiotech does not assume any legal responsibility if the information and references on our site are caused by misuse or misuse. The information on our site is intended for the target users, this information cannot be distributed or copied by third parties. Unauthorized use of trademarks and texts on our site is prohibited. All users using our site are deemed to have fully accepted this legal notice.
You can access our site after this warning if you confirm that you are a health worker (doctor, pharmacist, dentist etc.).
If you approve that you are a health worker (doctor, pharmacist, dentist, etc.), click on the button orum I accept lıy and if you do not approve, press the imi I do not accept ecz button.